Healthcare Industry News:  Mylan Laboratories 

Biopharmaceuticals Generics FDA

 News Release - August 10, 2007

Mylan Announces Final FDA Approval for Verapamil Hydrochloride Extended-Release Capsules (PM)

PITTSBURGH, Aug. 10 (HSMN NewsFeed) -- Mylan Laboratories Inc. (NYSE: MYL ) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Verapamil Hydrochloride (HCl) Extended-release (ER) Capsules (PM), 100 mg, 200 mg and 300 mg.

Verapamil HCl ER Capsules (PM) are the generic version of Elan Drug Delivery Inc.'s VerelanĀ® PM ER Capsules. Verapamil HCl ER Capsules (PM) had U.S. sales of approximately $58 million for the 12 months ending June 30, 2007, for the same strengths.

This product will be shipped immediately.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit

Source: Mylan Laboratories

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.